Table 2.
PARP inhibitor clinical trials in maintenance ovarian cancer treatment and related toxicity.
| Agent | Study | Drug-related Grade 3 / 4 AEs | Dose interruption | Dose reduction | Dose discontinuation | MDS/AML** | Treatment Deaths | References |
|---|---|---|---|---|---|---|---|---|
| Olaparib | Study2/24/9 12/20/42 (n=223) | 54.0% | 40.0% | 4.0% | 7.0% | 2.0% | 3.6% | 136 |
| Study 19 (n=136) | 35.3% | 27.9% | 22.8% | 2.2% | 2.0% | 0% | 137 | |
| SOLO2 (n=195) | 36.0% | 45.0% | 25.0% | 11.0% | 2.0% | 1.0% | 126 | |
| SOLO1 (n=260) | 39.0% | 52.0% | 28.0% | 12.0% | 1.0% | 0% | 125 | |
| Rucaparib | ARIEL2 + Study10 (n=377) | 60.7% | 58.6% | 45.9% | 10.0% | 0.5% | 0% | 138 |
| ARIEL3 (n=372) | 56.0% | 64.0% | 55.0% | 13.0% | 1.0% | 1.0% | 133 | |
| Niraparib | NOVA (n=367) | 64.6% | 68.9% | 66.5% | 14.7% | 1.4% | 0.3% | 134 |
| PRIMA (n=484) | 65.3% | 79.5% | 70.9% | 12.0% | 0.3% | 0% | 22 | |
| Olaparib / BEV | PAOLA-1 (n=535) | 57.0% | 54.0% | 41.0% | 41.0% | 1.0% | 0% | 41 |
| Veliparib | VELIA (n=382) | 88.0% | 41% | 24% | 19% | 0.2% | 0% | 34 |